

ASX ANNOUNCEMENT

IVB Signs Agreement with Novartis Pharma

Resonance Health is pleased to announce an expansion of the cooperation between its subsidiary Inner Vision Biometrics Pty Ltd (“IVB”) and the international pharmaceutical group Novartis in relation to the FerriScan diagnostic test.

FerriScan is a newly developed non invasive test for iron overload in the body which utilizes magnetic resonance imaging. Iron overload diseases are amongst the most common genetic disorders and are a significant cause of mortality around the world.

During the past 12 months IVB and Novartis Pharma, a major Swiss based multinational pharmaceutical group, have cooperated on a Novartis drug development program relating to iron overload. IVB has been working with Novartis to provide FerriScan testing services in connection with several major clinical studies about to be undertaken by Novartis as part of this program.

IVB and Novartis have concluded an agreement which will expand the provision of FerriScan testing services to Novartis to include an additional three overseas clinical trials relating to iron overload diseases.

IVB’s expanded involvement will include the use of the FerriScan diagnostic test at a variety of new centres in the U.S. and the Middle East, in addition to existing trial locations in Europe and the U.S.

“IVB is pleased to further cement its cooperation with Novartis in the lead up to FerriScan’s planned international introduction in 2004/2005”. Resonance Health’s Managing Director Tony Fitzgerald said, “IVB and Resonance have a strong interest in iron overload disorders and are pursuing initiatives aimed at improving the treatment and quality of life of people suffering these diseases”.

About Resonance

Resonance Health (formerly GEO2 Limited) acquired a controlling interest in the FerriScan technology in November 2003. Resonance Health owns 51% of Inner Vision Biometrics, the developer of FerriScan, a novel, non-invasive liver diagnosis technology. The technology taps a strong and growing demand worldwide for new non invasive diagnostic and monitoring techniques.

About FerriScan

The importance of early diagnosis and the ability to accurately monitor iron concentration within the liver is crucial to the management of chronic iron disorders and the long term health of the patient.

The FerriScan test assists in the diagnosis and monitoring of iron overload diseases without the need for invasive procedures. FerriScan is aimed primarily at detecting iron toxicity and then monitoring the effectiveness of ongoing treatment. FerriScan testing may also be helpful in the management of hepatitis, which has an incidence of over 1:100 in developed countries.

For further information:	
Media / investor relations	Company
Rebecca Christie, Buchan (02) 9293 2836 0417 382 391 rchristie@bcg.com.au	Mr Tony Fitzgerald, Managing Director Resonance Health Limited (08) 9389 5933 0418 903 647 tfitzgerald@resonancehealth.com